These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 33569825)

  • 1. Safety of apixaban compared to warfarin in hemodialysis patients: Do antiplatelets make a difference?
    Ionescu F; Cooper C; Petrescu I; George J; Mansuri S
    Eur J Haematol; 2021 May; 106(5):689-696. PubMed ID: 33569825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States.
    Siontis KC; Zhang X; Eckard A; Bhave N; Schaubel DE; He K; Tilea A; Stack AG; Balkrishnan R; Yao X; Noseworthy PA; Shah ND; Saran R; Nallamothu BK
    Circulation; 2018 Oct; 138(15):1519-1529. PubMed ID: 29954737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Application and Pharmacodynamic Monitoring of Apixaban in a Patient with End-Stage Renal Disease Requiring Chronic Hemodialysis.
    Kufel WD; Zayac AS; Lehmann DF; Miller CD
    Pharmacotherapy; 2016 Nov; 36(11):e166-e171. PubMed ID: 27643979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin.
    Brekelmans MP; Scheres LJ; Bleker SM; Hutten BA; Timmermans A; Büller HR; Middeldorp S
    Thromb Haemost; 2017 Apr; 117(4):809-815. PubMed ID: 28180233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease.
    Schafer JH; Casey AL; Dupre KA; Staubes BA
    Ann Pharmacother; 2018 Nov; 52(11):1078-1084. PubMed ID: 29871510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing the Safety Profile of Apixaban Versus Warfarin in Moderate to Severe Chronic Kidney Disease at a Veterans Affairs Hospital.
    Herndon K; Guidry TJ; Wassell K; Elliott W
    Ann Pharmacother; 2020 Jun; 54(6):554-560. PubMed ID: 31872779
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience.
    Heleniak Z; Papuga-Szela E; Krzysztof P; Anetta U
    J Cardiovasc Pharmacol; 2020 Dec; 76(6):671-677. PubMed ID: 33284572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial.
    Cohen AT; Agnelli G; Buller HR; Gallus A; Raskob GE; Sanders P; Thompson J; Weitz JI
    Thromb Haemost; 2019 Mar; 119(3):461-466. PubMed ID: 30650446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
    Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
    J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety Outcomes of Apixaban Compared With Warfarin in Patients With End-Stage Renal Disease.
    Sarratt SC; Nesbit R; Moye R
    Ann Pharmacother; 2017 Jun; 51(6):445-450. PubMed ID: 28478715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation.
    Nagao T; Inden Y; Shimano M; Fujita M; Yanagisawa S; Kato H; Ishikawa S; Miyoshi A; Okumura S; Ohguchi S; Yamamoto T; Yoshida N; Hirai M; Murohara T
    Pacing Clin Electrophysiol; 2015 Feb; 38(2):155-63. PubMed ID: 25487164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
    Halvorsen S; Ghanima W; Fride Tvete I; Hoxmark C; Falck P; Solli O; Jonasson C
    Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):28-36. PubMed ID: 27680880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of oral anticoagulation choice on healthcare utilization for the primary treatment of venous thromboembolism.
    Lutsey PL; MacLehose RF; Claxton JS; Walker RF; Adam TJ; Alonso A; Zakai NA
    Vasc Med; 2020 Dec; 25(6):549-556. PubMed ID: 32716254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population-based cohort study.
    Cheung CL; Sing CW; Lau WCY; Li GHY; Lip GYH; Tan KCB; Cheung BMY; Chan EWY; Wong ICK
    Cardiovasc Diabetol; 2021 Mar; 20(1):71. PubMed ID: 33766030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation.
    Bahit MC; Lopes RD; Wojdyla DM; Held C; Hanna M; Vinereanu D; Hylek EM; Verheugt F; Goto S; Alexander JH; Wallentin L; Granger CB
    Heart; 2017 Apr; 103(8):623-628. PubMed ID: 27798052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
    Agnelli G; Buller HR; Cohen A; Gallus AS; Lee TC; Pak R; Raskob GE; Weitz JI; Yamabe T
    J Thromb Haemost; 2015 Dec; 13(12):2187-91. PubMed ID: 26407753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial.
    Alexander JH; Lopes RD; Thomas L; Alings M; Atar D; Aylward P; Goto S; Hanna M; Huber K; Husted S; Lewis BS; McMurray JJ; Pais P; Pouleur H; Steg PG; Verheugt FW; Wojdyla DM; Granger CB; Wallentin L
    Eur Heart J; 2014 Jan; 35(4):224-32. PubMed ID: 24144788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.